Bayer's Actron OTC ketoprofen set to launch "within weeks".
This article was originally published in The Tan Sheet
Executive Summary
BAYER'S ACTRON OTC KETOPROFEN LAUNCH COMING "WITHIN WEEKS," the company said, following FDA's Oct. 6 approval of the 12.5 mg strength of the NSAID for OTC analgesic indications. Calling Actron "extremely important" to the company and promising a "formidable launch," Bayer said it intends to support its new Rx-to-OTC switch with major promotional campaigns directed at consumers, physicians and pharmacists.